Skip to content

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508085-15-00
Acronym
LTS18133
Enrollment
247
Registered
2024-04-29
Start date
2024-05-15
Completion date
Unknown
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Incidence of treatment‑emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation

Detailed description

Functional itepekimab concentrations in serum, Incidence of treatment emergent (TE) anti-drug antibody responses, Annualized rate of moderate to severe acute exacerbation of COPD (AECOPD), Annualized rate of severe AECOPD, Time to first moderate-to-severe AECOPD, Time to first severe AECOPD, Change from baseline of the parent studies (EFC16750, EFC16819): Pre-BD and post-BD FEV1, Change from baseline of the parent studies (EFC16750, EFC16819): SGRQ total score and domain scores, Change from baseline of the parent studies (EFC16750, EFC16819): EQ-5D-5L single index score, Change from baseline of the parent studies (EFC16750, EFC16819): EQ-VAS, Change from Week 0 for CASA-Q

Interventions

Sponsors

Sanofi-Aventis Recherche & Developpement
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Incidence of treatment‑emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation

Secondary

MeasureTime frame
Functional itepekimab concentrations in serum, Incidence of treatment emergent (TE) anti-drug antibody responses, Annualized rate of moderate to severe acute exacerbation of COPD (AECOPD), Annualized rate of severe AECOPD, Time to first moderate-to-severe AECOPD, Time to first severe AECOPD, Change from baseline of the parent studies (EFC16750, EFC16819): Pre-BD and post-BD FEV1, Change from baseline of the parent studies (EFC16750, EFC16819): SGRQ total score and domain scores, Change from baseline of the parent studies (EFC16750, EFC16819): EQ-5D-5L single index score, Change from baseline of the parent studies (EFC16750, EFC16819): EQ-VAS, Change from Week 0 for CASA-Q

Countries

Bulgaria, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026